The IMS-IMWG 2025 staging system provides a vital tool for managing newly diagnosed multiple myeloma (NDMM). This model integrates genomic data to define high-risk (HR) subsets accurately. Furthermore, clinicians now use this system to improve consistency in clinical trial reporting. Researchers recently validated these criteria in patients receiving daratumumab-based quadruplet therapy.

Specifically, a study analyzed 503 NDMM patients at Memorial Sloan Kettering Cancer Center. These patients underwent induction with anti-CD38 monoclonal antibody quadruplets. Consequently, findings showed that the new definition delineates risk better than legacy scores. Notably, the criteria identified 31% of patients as high-risk.

Impact of IMS-IMWG 2025 staging on Survival

Although modern therapy is potent, survival differences remain significant. Interestingly, the IMS-IMWG 2025 staging did not predict early minimal-residual disease (MRD) negativity. HR and standard-risk (SR) patients reached MRD negativity at nearly identical rates. However, the genomic staging strongly predicted long-term survival outcomes.

Specifically, HR patients had a median progression-free survival (PFS) of only 2.6 years. In contrast, the median PFS for SR patients was not reached (p < 0.001). Moreover, the model predicted overall survival (OS) with high statistical significance (p = 0.003). Therefore, this staging system is essential for identifying patients who require closer monitoring or novel interventions.

Frequently Asked Questions

What unique features are included in the 2025 staging?

It is the first to include TP53 mutations and specific co-occurrences of IgH translocations with chromosome 1 aberrations.

Does the new staging predict overall survival?

Yes, the study demonstrated that the genomic criteria effectively predict both progression-free survival and overall survival.

Disclaimer: This content is for informational and educational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Maclachlan KH et al. IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM. Blood Adv. 2026 Feb 17. doi: undefined. PMID: 41701976.

Avet-Loiseau H, et al. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025;43(24):2739-2751.

International Myeloma Foundation. IMS-IMWG Consensus Definition of HRMM. June 2025.